Loading...
Pulmonary infection with the nontuberculous mycobacterium M. abscessus is associated with multidrug resistance and poor outcomes. Current treatment approaches require prolonged courses of multiple antibiotics with intervals of intravenous agents. New therapies are urgently needed.
In a new industry-supported study, researchers evaluated omadacycline — a tetracycline antibiotic approved for bacterial pneumonia and skin and soft-tissue infections with in vitro activity against M. abscessus — as an oral once-daily monotherapy for noncavitary M. abscessus lung infection. Sixty-six patients were randomized to receive omadacycline or placebo for 84 days. Outcomes included patient-reported symptoms and microbiological clearance from respirat…